Bechmann Lab - Neurochemistry

• Since 2023: Head of Neurochemistry Lab
• Since 2021: Principle Investigator, Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus of Technische Universität Dresden (TUD), Germany
• 2020–2021: PostDoc, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Germany
• 2015–2020: PostDoc, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden (TUD), Germany
• 2011 - 2015: PhD Student, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Saxony, Germany 

Sexual dimorphism adrenal tumors

• Bechmann N, Moskopp ML, Constantinescu G, Stell A, Ernst A, Berthold F, ... & Eisenhofer G. Asymmetric Adrenals: Sexual Dimorphism of Adrenal Tumors. The Journal of Clinical Endocrinology & Metabolism, 2024 109(2), 471-482.
• Richter S, & Bechmann N. Patient sex and origin influence distribution of driver genes and clinical presentation of paraganglioma. Journal of the Endocrine Society, 2024 bvae038.

Hypoxia signaling in pheochromocytomas and paragangliomas

• Bechmann N, Moskopp ML, Ullrich M, Calsina B, Wallace PW, Richter S, Friedemann M, Langton K, Fliedner SMJ, Timmers HJLM, Nölting S, Beuschlein F, Fassnacht M, Prejbisz A, Pacak K, Ghayee HK, Bornstein SR, Dieterich P, Pietzsch J, Wielockx B, Robledo M, Qin N, Eisenhofer G. HIF2α supports pro-metastatic behavior in pheochromocytomas/ paragangliomas. Endocr Relat Cancer 2020 Nov;27(11):625-640.
• Bechmann N, Poser I, Seifert V, Greunke C, Ullrich M, Qin N, Walch A, Peitzsch M, Robledo M, Pacak K, Pietzsch J, Richter S, Eisenhofer G. Impact of extrinsic and intrinsic hypoxia on catecholamine biosynthesis in absence or presence of Hif2α in pheochromocytoma cells. Cancers 2019, 11 (5), 594.
• Helm J, Drukewitz S, Poser I, Richter S, Friedemann M, William D, Mohr H, Nölting S, Robledo M, Bornstein SR, Eisenhofer G, Bechmann N. Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model. Cells 2022, 11(3):560.

Novel therapeutic options for pheochromocytomas and paragangliomas

• Bechmann N, Ehrlich H, Eisenhofer G, Ehrlich A, Meschke S, Ziegler CG, Bornstein SR. Anti-Tumorigenic and Anti-Metastatic Activity of the Sponge-Derived Marine Drugs Aeroplysinin-1 and isofistularin-3 against pheochromocytoma in vitro. Marine Drugs 2018 May, 16(5), 172.
• Drechsel A, Helm J, Ehrlich H, Pantovic S, Bornstein SR, Bechmann N. Anti-tumor activity vs. normal cell toxicity: Therapeutic potential of the bromotyrosines aerothionin and homoaerothionin in vitro. Marine Drugs 2020 May, 18(5), 236.
• Bechmann N, Calsina B, Richter S, Pietzsch J. Therapeutic potential of nitric oxide releasing selective estrogen receptor modulators (NO-SERMs) in malignant melanoma. Journal of Investigative Dermatology 2022 142(8), 2217-2227.

Metabolic differences in adrenal tumors

• Langner M, Fröbel D, Helm J, Chavakis T, Peitzsch M, & Bechmann N. Accurate redox state indication by in situ derivatization with N-ethylmaleimide-Profiling of transsulfuration and glutathione pathway metabolites by UPLC-MS/MS. Journal of Chromatography B, 2024 124062.
• Bechmann N, Watts D, Steenblock C, Wallace PW, Schürmann A, Bornstein SR, Wielockx B, Eisenhofer G, Peitzsch M. Adrenal Hormone Interactions and Metabolism: A Single Sample Multi-Omics Approach. Horm Metab Res. 2021 May;53(5):326-334.

Complete list of published work: https://scholar.google.com/scholar?hl=de&as_sdt=0%2C5&q=nicole+bechmann&btnG=